Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients

[1]  Han Liu,et al.  Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens , 2018, Journal of Translational Medicine.

[2]  T. Graubert,et al.  High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. , 2018, Blood.

[3]  Han Liu,et al.  Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML) , 2018, Journal of Translational Medicine.

[4]  G. Boucher,et al.  Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity , 2017, Clinical Cancer Research.

[5]  Wei Zhang,et al.  Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution , 2017, Leukemia & lymphoma.

[6]  M. Goodell,et al.  DNMT3A in Leukemia. , 2017, Cold Spring Harbor perspectives in medicine.

[7]  Wei Liu,et al.  Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells , 2017, Scientific Reports.

[8]  Francine E. Garrett-Bakelman,et al.  DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling , 2016, Nature Medicine.

[9]  Wei Zhang,et al.  Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients. , 2016, Pharmacogenomics.

[10]  Jiye Yin,et al.  Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients , 2016, Oncotarget.

[11]  Xiao-Qing Yuan,et al.  DNMT3A R882 Mutations Predict a Poor Prognosis in AML , 2016, Medicine.

[12]  O. Abdel-Wahab,et al.  Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. , 2016, Blood.

[13]  Y. Kim,et al.  Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length , 2015, Blood Cancer Journal.

[14]  R. Hills,et al.  Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Gimotty,et al.  DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia , 2015, Clinical Cancer Research.

[16]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[17]  R. Majeti,et al.  Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis , 2014, Leukemia.

[18]  Sören Lehmann,et al.  Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes , 2014, Epigenetics.

[19]  Christopher A. Miller,et al.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. , 2014, Cancer cell.

[20]  T. Brümmendorf,et al.  Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia , 2013, Leukemia.

[21]  S. Henikoff,et al.  Doxorubicin, DNA torsion, and chromatin dynamics. , 2014, Biochimica et biophysica acta.

[22]  A. Singh,et al.  A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. , 2013, Blood.

[23]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[24]  A. Jemal,et al.  Outcome of older patients with acute myeloid leukemia , 2013, Cancer.

[25]  R. Greil,et al.  Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). , 2013, Blood.

[26]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[27]  Jacques Neefjes,et al.  Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin , 2013, Nature Communications.

[28]  S. Henikoff,et al.  Doxorubicin Enhances Nucleosome Turnover around Promoters , 2013, Current Biology.

[29]  F. Ferrara,et al.  Acute myeloid leukaemia in adults , 2013, The Lancet.

[30]  R. Sankila,et al.  Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study , 2013, Haematologica.

[31]  J. Radich,et al.  Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report , 2013, Leukemia.

[32]  Mithat Gonen,et al.  Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis , 2012, Nature Genetics.

[33]  N. Reich,et al.  Mutations in DNA Methyltransferase (DNMT3A) Observed in Acute Myeloid Leukemia Patients Disrupt Processive Methylation , 2012, The Journal of Biological Chemistry.

[34]  Veronika Rockova,et al.  Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. , 2012, Blood.

[35]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[36]  M. Caligiuri,et al.  Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Berg,et al.  Dnmt3a is essential for hematopoietic stem cell differentiation , 2011, Nature Genetics.

[38]  Chieh-Yu Liu,et al.  DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. , 2012, Blood.

[39]  E. Estey,et al.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  He Huang,et al.  A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome , 2011, Journal of hematology & oncology.

[41]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[42]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[44]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[45]  J. Alsner,et al.  Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. , 1992, Journal of molecular biology.

[46]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia , 1992 .

[47]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.

[48]  J. Yates,et al.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. , 1973, Cancer chemotherapy reports.